stockrow
Saturday 7 November 2026
Export VYGR’s income statement to Excel — free account
Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024.
- Revenue
- −70.0%
- EPS
- +14.9%
- Free cash flow
- +37.1%
Quarter to September 2026, against a year earlier
1.90
0.18
+10.47%
Follow VYGR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.71 | 6.29 | 6.15 | 6.60 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.62) | (6.87) | (8.20) | (8.43) | |
P/B ratio |
1.18 | 1.32 | 1.37 | 1.23 | |
Price to Tangible BV |
1.18 | 1.32 | 1.37 | 1.23 | |
EV/Sales |
0.85 | 2.42 | 2.77 | 2.35 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.26) | (0.69) | (0.79) | (0.54) | |
EV/FCF |
(0.25) | (0.68) | (0.79) | (0.54) | |
Quick Ratio |
7.47 | 8.20 | 7.16 | 6.61 | |
Current Ratio |
7.64 | 8.42 | 7.51 | 6.81 | |
Net Debt/EBITDA |
6.68 | 4.76 | 4.52 | 4.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.13 | 0.13 | 0.11 | |
Operating CF/Net income |
1.10 | 1.20 | 1.06 | 0.80 | |
Capex/Depreciation |
(1.21) | (0.02) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
234.43% | 948.79% | 696.40% | 607.15% | |
Selling, General and Administrative Expense of Revenue |
60.75% | 318.59% | 237.47% | 151.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
22.96% | 95.95% | 76.87% | 64.85% | |
Graham Net Nets |
0.64 | 0.44 | 0.39 | 0.44 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(51.91%) | (51.30%) | (51.71%) | (64.93%) | |
Free Cash Flow Yield |
(58.56%) | (56.58%) | (57.30%) | (66.41%) | |
Revenue per Share |
0.26 | 0.04 | 0.05 | 0.06 | |
Operating CF per Share |
(0.52) | (0.56) | (0.43) | (0.32) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.53) | (0.56) | (0.43) | (0.32) | |
Cash per Share |
3.35 | 2.38 | 1.92 | 1.73 | |
Shareholders Equity per Share |
3.34 | 2.92 | 2.55 | 2.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.34 | 2.92 | 2.55 | 2.19 | |
Free Cash Flow |
(30.89) | (33.43) | (25.84) | (19.67) | |
Working Capital |
176.15 | 129.53 | 108.54 | 97.62 | |
Capital Expenditures |
(0.63) | (0.01) | 0.00 | — | |
Net Current Asset Value |
146.49 | 101.33 | 81.85 | 72.49 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.05 | 1.88 | 2.84 | 4.16 | |
Average Payables |
4.50 | 2.68 | 1.71 | 2.03 | |
Average Assets |
322.67 | 286.28 | 259.93 | 232.68 | |
Average Common Equity |
247.92 | 223.19 | 199.16 | 177.47 |
Columns are period end dates · fundamentals updated 5 Nov 2026